Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
07 Agosto 2024 - 9:42AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2024
Commission File Number: 001-34563
CONCORD MEDICAL SERVICES HOLDINGS LIMITED
Room A1-A5 26/F, East Zone, Hanwei Plaza
No. 7 Guanghua Road, Chaoyang District,
Beijing 100020
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Exhibit Index
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
CONCORD MEDICAL SERVICES HOLDINGS LIMITED |
|
|
|
|
By: |
/s/ Jianyu Yang |
|
Name: |
Jianyu Yang |
|
Title: |
Chairman and Chief Executive Officer |
Date: August 7, 2024
Exhibit 99.1
Concord Medical Regains Compliance with NYSE
Minimum Price Requirement
BEIJING, August 7, 2024 /PRNewswire/ -- Concord
Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized
in cancer treatment, research, education and prevention in China, today announced that it has received a letter from the New York Stock
Exchange (“NYSE”) dated August 6, 2024 (the “Compliance Notice”), notifying the Company that it is no longer considered
below the NYSE’s continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period (the “NYSE
Minimum Price Requirement”).
As previously announced, the Company received a letter from the NYSE
dated February 12, 2024, notifying the Company that it was below compliance standards due to the trading price of its American Depositary
Shares. Following the receipt of the Compliance Notice, the Company is no longer considered below the NYSE Minimum Price Requirement,
and has regained compliance regarding this matter.
About Concord Medical
Concord Medical Services Holdings Limited is a
healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention.
The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals
and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving
to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered
hospitals across China. For more information, please see http://ir.ccm.cn.
About Concord Healthcare
Concord Healthcare is an oncology healthcare provider
in China. Concord Healthcare serves both cancer patients through self-owned medical institutions and third-party medical institutions
through medical equipment, software and related services. In its self-owned medical institutions, Concord Healthcare provides a full
spectrum of oncology healthcare services to cancer patients across the entire care continuum, leveraging its multidisciplinary team specialists
and diagnosis and treatment capabilities featuring precision radiation therapy. Through its medical equipment, software and related
services, Concord Healthcare serves a widespread network of enterprise customers, primarily hospitals, with integrated oncology-related
services, including primarily sales and installing of medical equipment and software, management and technical support, and operating
lease.
Safe Harbor Statement
This announcement contains forward-looking statements.
These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates” and similar expressions.
Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company’s control and based upon
premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results
to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
For more information, please contact:
Concord Medical Services Holdings Limited
Investor Relations
+86 10 5903 6688
ir@ccm.cn
Concord Medical Services (NYSE:CCM)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Concord Medical Services (NYSE:CCM)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024